Incidence of Atrial Fibrillation and Mineralocorticoid Receptor Activity in Patients With Medically and Surgically Treated Primary Aldosteronism

被引:168
|
作者
Hundemer, Gregory L. [1 ,2 ,3 ]
Curhan, Gary C. [1 ,2 ,3 ,4 ]
Yozamp, Nicholas [2 ,3 ]
Wang, Molin [2 ,3 ,4 ]
Vaidya, Anand [2 ,3 ,5 ]
机构
[1] Brigham & Womens Hosp, Dept Med, Div Renal Med, 75 Francis St, Boston, MA 02115 USA
[2] Harvard Med Sch, Boston, MA USA
[3] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA
[4] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Dept Biostat, Boston, MA USA
[5] Brigham & Womens Hosp, Dept Med, Div Endocrinol Diabet & Hypertens, Ctr Adrenal Disorders, 75 Francis St, Boston, MA 02115 USA
基金
美国国家卫生研究院;
关键词
ARTERIAL-HYPERTENSION; HYPERALDOSTERONISM; EPLERENONE;
D O I
10.1001/jamacardio.2018.2003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE Primary aldosteronism (PA) is an ideal condition to evaluate the role of the mineralocorticoid receptor (MR) in the pathogenesis of atrial fibrillation (AF). OBJECTIVE To investigate whether MR antagonist therapy or surgical adrenalectomy in PA influence the risk for incident AF. DESIGN This cohort study included patients aged 18 years and older. Patients with PA and age-matched patients with essential hypertension were identified via electronic health records. Patients with a history of AF, myocardial infarction, congestive heart failure, or stroke were excluded. Data were collected between 1991 and the end of 2016 in an academic medical center, with a mean follow-up duration of approximately 8 years. EXPOSURES Patients with PA treated with MR antagonists or surgical adrenalectomy were compared with patients with essential hypertension. Patients with PA who were treated with MR antagonists were categorized by whether their plasma renin activity remained suppressed (< 1 ng/mL/h) or substantially increased (>= 1 ng/mL/h), as proxies for insufficient or sufficient MR blockade. MAIN OUTCOMES AND MEASURE Incident AF. RESULTS A total of 195 patients with PA who were treated with MR antagonists and 201 patients with PA treated with surgical adrenalectomy were included, as well as 40 092 age-matched patients with essential hypertension. Despite similar blood pressure at study entry and throughout follow-up, patients with PA who were treated with MR antagonists whose renin remained suppressed had a higher risk for incident AF than patients with essential hypertension (adjusted HR, 2.55 [95% CI, 1.75-3.71]). They also had an adjusted 10-year cumulative AF incidence difference of 14.1(95% CI, 6.7-21.5) excess cases per 100 persons compared with patients with essential hypertension. In contrast, patients with PA who were treated with MR antagonists and whose renin increased and patients with PA who were treated with surgical adrenalectomy had no statistically significant difference in risk for incident AF compared with patients with essential hypertension. CONCLUSIONS AND RELEVANCE When compared with patients with essential hypertension, patients with PA treated with MR antagonists such that renin remained suppressed (as a proxy for insufficient MR blockade) had a significantly higher risk for incident AF; however, treatment of PA with MR antagonists to substantially increase renin (suggesting sufficient MR blockade), or with surgical adrenalectomy (to remove the source of aldosteronism), was associated with no significant difference in risk for developing AF. These findings add to the growing body of evidence suggesting that MR blockade may be a potential therapy to decrease the incidence of AF.
引用
收藏
页码:768 / 774
页数:7
相关论文
共 50 条
  • [1] Hyperkalemia in both surgically and medically treated patients with primary aldosteronism
    N Wada
    Y Shibayama
    H Umakoshi
    T Ichijo
    Y Fujii
    K Kamemura
    T Kai
    R Sakamoto
    A Ogo
    Y Matsuda
    T Fukuoka
    M Tsuiki
    T Suzuki
    M Naruse
    Journal of Human Hypertension, 2017, 31 : 627 - 632
  • [2] Hyperkalemia in both surgically and medically treated patients with primary aldosteronism
    Wada, N.
    Shibayama, Y.
    Umakoshi, H.
    Ichijo, T.
    Fujii, Y.
    Kamemura, K.
    Kai, T.
    Sakamoto, R.
    Ogo, A.
    Matsuda, Y.
    Fukuoka, T.
    Tsuiki, M.
    Suzuki, T.
    Naruse, M.
    JOURNAL OF HUMAN HYPERTENSION, 2017, 31 (10) : 627 - 632
  • [3] Renal Outcomes in Medically and Surgically Treated Primary Aldosteronism
    Hundemer, Gregory L.
    Curhan, Gary C.
    Yozamp, Nicholas
    Wang, Molin
    Vaidya, Anand
    HYPERTENSION, 2018, 72 (03) : 658 - 666
  • [4] Persistent cardiac organ damage in surgically and medically treated primary aldosteronism
    Aune, Arleen
    Gerdts, Eva
    Kokorina, Marina
    Kringeland, Ester
    Midtbo, Helga
    Lovas, Kristian
    Grytaas, Marianne A.
    JOURNAL OF HYPERTENSION, 2022, 40 (06) : 1204 - 1211
  • [5] Reversal of arterial stiffness in medically and surgically treated unilateral primary aldosteronism
    Chen, Zheng-Wei
    Liao, Che-Wei
    Pan, Chien-Ting
    Tsai, Cheng-Hsuan
    Chang, Yi-Yao
    Chang, Chin-Chen
    Lee, Bo-Ching
    Chiu, Yu-Wei
    Huang, Wei-Chieh
    Lai, Tai-Shuan
    Lu, Ching-Chu
    Chueh, Jeff S.
    Wu, Vin-Cent
    Hung, Chi-Sheng
    Lin, Yen-Hung
    JOURNAL OF HYPERTENSION, 2024, 42 (03) : 538 - 545
  • [6] Prediction of endogenous mineralocorticoid receptor activity by depressor effects of mineralocorticoid receptor antagonists in patients with primary aldosteronism
    Ikemoto, Makiko
    Morimoto, Satoshi
    Ichihara, Atsuhiro
    HYPERTENSION RESEARCH, 2024, 47 (06) : 1707 - 1718
  • [7] Primary Aldosteronism Testing for Patients With Atrial Fibrillation
    Dudley, Stephen
    AMERICAN FAMILY PHYSICIAN, 2024, 110 (01) : 11 - 11
  • [8] Subtype Identification of Surgically Curable Primary Aldosteronism During Treatment With Mineralocorticoid Receptor Blockade
    Pintus, Giovanni
    Seccia, Teresa Maria
    Amar, Laurence
    Azizi, Michel
    Riester, Anna
    Reincke, Martin
    Widimsky, Jiri
    Naruse, Mitsuhide
    Kocjan, Tomaz
    Negro, Aurelio
    Kline, Gregory
    Tanabe, Akiyo
    Satoh, Fumitoshi
    Rump, Lars Christian
    Vonend, Oliver
    Fuller, Peter J.
    Yang, Jun
    Chee, Nicholas Yong Nian
    Magill, Steven B.
    Shafigullina, Zulfiya
    Quinkler, Marcus
    Oliveras, Anna
    Lee, Bo-Ching
    Chang, Chin-Chen
    Wu, Vin-Cent
    Kratka, Zuzana
    Battistel, Michele
    Bagordo, Domenico
    Caroccia, Brasilina
    Ceolotto, Giulio
    Rossitto, Giacomo
    Rossi, Gian Paolo
    HYPERTENSION, 2024, 81 (06) : 1391 - 1399
  • [9] Atrial Fibrillation in Primary Aldosteronism
    Pan, Chien-Ting
    Tsai, Cheng-Hsuan
    Chen, Zheng-Wei
    Chang, Yi-Yao
    Wu, Vin-Cent
    Hung, Chi-Sheng
    Lin, Yen-Hung
    HORMONE AND METABOLIC RESEARCH, 2020, 52 (06) : 357 - 365
  • [10] Mineralocorticoid receptor signalling in primary aldosteronism
    Yang, Jun
    Young, Morag J.
    Cole, Timothy J.
    Fuller, Peter J.
    JOURNAL OF ENDOCRINOLOGY, 2023, 259 (01)